DARE - Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting | Benzinga
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will present at the 2023 Annual Meeting of The Menopause Society (formerly known as The North American Menopause Society, or NAMS) taking place September 27-30, 2023 at the Marriott Downtown in Philadelphia, PA. Additionally, three poster presentations relating to two of Daré's investigational products designed to address common menopausal symptoms will be shared at the meeting.
| Presentation: |
| Not All Vulvodynia is Genitourinary Syndrome of Menopause |
| Presenter: |
| Andrew T. Goldstein, MD, FACOG |
| Director, The Centers for Vulvovaginal Disorders |
| Clinical Professor, George Washington University School of Medicine |
| Date / Time: |
| Saturday, September 30, 2023, 9:35 -9:55 a.m. EDT |
Poster Presentations*:
- A Phase 1/2, Open-label, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of DARE-HRT1 (80 ?g Estradiol/4 mg Progesterone and 160 ?g Estradiol/8 mg Progesterone Intravaginal Rings) Over 12 Weeks in Healthy Postmenopausal Women
- A Phase 1/2, Open-label, Parallel Group Study to Evaluate the Preliminary Efficacy and Usability of DARE-HRT1 (80 ?g Estradiol/4 mg Progesterone and 160 ?g Estradiol/8 mg Progesterone) Intravaginal Rings Over 12 Weeks in Healthy Postmenopausal Women
- Pharmacokinetics, Safety and Preliminary Pharmacodynamic Evaluation of DARE-VVA1: A Soft Gelatin Capsule containing Tamoxifen for the Treatment of the Genitourinary Syndrome of Menopause
*Authors: Andrea Thurman, MD1; M. Louise Hull, MBChB, PhD, FRANZCOG2; Bronwyn Stuckey, MBBS, FRACP3; Jessica Hatheway, MBA1; Christine Mauck, MD, MPH1; Nadene Zack, MS1; and David Friend, ...